Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, randomized, open-label with blind evaluation, non-inferiority clinical trial, with parallel groups to evaluate the efficacy and safety of the topical application of Impetine® Gel (mupirocin 20 mg/g, Gel) compared with Bactroban® (mupirocin 20 mg/g, Ointment) for the treatment of impetigo in paediatric population - OP-IPTC02

Trial Profile

Multicenter, randomized, open-label with blind evaluation, non-inferiority clinical trial, with parallel groups to evaluate the efficacy and safety of the topical application of Impetine® Gel (mupirocin 20 mg/g, Gel) compared with Bactroban® (mupirocin 20 mg/g, Ointment) for the treatment of impetigo in paediatric population - OP-IPTC02

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mupirocin (Primary) ; Mupirocin
  • Indications Impetigo
  • Focus Registrational; Therapeutic Use
  • Acronyms OP-IPTC02
  • Sponsors Ojer Pharma

Most Recent Events

  • 12 Sep 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top